Pyxis Oncology to webcast updated Phase 1 MICVO monotherapy data in recurrent/metastatic head and neck cancer

PUBT · 1d ago
Pyxis Oncology to webcast updated Phase 1 MICVO monotherapy data in recurrent/metastatic head and neck cancer
  • Pyxis Oncology scheduled a Sept. 9, 2026 webcast to present updated Phase 1 monotherapy data for micvotabart pelidotin in 2L+ R/M HNSCC.
  • Results have not yet been presented; the update will be delivered during the webcast.
  • Management will outline how the latest findings shape the program’s risk-benefit profile in a hard-to-treat setting.
  • The company will also frame next clinical development steps, a key input for timelines, partnering prospects, and future funding needs.
  • MICVO holds FDA Fast Track status for adults whose disease progressed after platinum chemotherapy and anti-PD-(L)1 therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609081601PRIMZONEFULLFEED9823127) on September 08, 2026, and is solely responsible for the information contained therein.